|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:academic_programs
|
Dr. Susan M. Houghton
|
|
gptkbp:accreditation
|
gptkb:CLIA
gptkb:ISO_13485
CAP
|
|
gptkbp:acquisition
|
gptkb:Myriad_RBM
Cynvenio Biosystems
SOPHi A GENETICS
|
|
gptkbp:advertising
|
gptkb:Ms._Jennifer_L._Smith
Mr. Robert J. Johnson
Ms. Linda K. Brown
|
|
gptkbp:case_analysis
|
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics
Myriad Genetics, Inc. v. United States
|
|
gptkbp:ceo
|
Randy Scott
|
|
gptkbp:clinical_trial
|
Myriad my Risk
Myriad my Choice
Myriad my Plan
Myriad my Risk for Prostate Cancer
Myriad my Choice CDx
|
|
gptkbp:conducts_research_on
|
Dr. Jerry L. Spivak
|
|
gptkbp:employees
|
~1,000
|
|
gptkbp:focus_area
|
gptkb:Oncology
Mental Health
Cardiovascular Health
Rare Diseases
Women's Health
|
|
gptkbp:founded
|
gptkb:1991
|
|
gptkbp:founder
|
gptkb:Mark_Skolnick
|
|
gptkbp:head
|
Mr. Thomas R. Anderson
|
|
gptkbp:head_of_clinical
|
Dr. David E. Goldgar
|
|
gptkbp:head_of_regulatory
|
gptkb:Dr._John_D._Mc_Carthy
|
|
gptkbp:head_of_state
|
gptkb:Mr._Michael_J._Mc_Carthy
Ms. Patricia A. Williams
|
|
gptkbp:headquarters
|
gptkb:Salt_Lake_City,_Utah
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Myriad Genetics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:invention
|
Gene patenting
BRCA1 and BRCA2 genes
|
|
gptkbp:notable_products
|
BRACAnalysis
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
|
|
gptkbp:revenue
|
$1 billion (2020)
|
|
gptkbp:specializes_in
|
Genetic testing
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:MYGN
|
|
gptkbp:website
|
myriad.com
|
|
gptkbp:bfsParent
|
gptkb:BRCA2
|
|
gptkbp:bfsLayer
|
5
|